Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07174622
Recruiting Observational

Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation

NCT07174622 · tracked via the Priya Life Science USA tracker
Sponsor
Medtronic Vascular
Phase
Observational
Started
2025-10-28
Last updated
2026-10-20

Condition(s) studied

HypertensionCardiovascular DiseasesVascular Diseases

Investigational drug(s) / intervention(s)

Renal Denervation (Symplicity Spyral™)

Renal Denervation (Symplicity Spyral™): Symplicity Spyral™ multi-electrode renal denervation system

Study summary

This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension. This research will be conducted using de-identified electronic health records (EHR) and administrative health insurance claims data. Patients are enrolled through the submission of claims or encounter data to CMS.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Enrolled in a Medicare plan * Diagnosis of uncontrolled hypertension * On a stable regimen of antihypertensive therapy Exclusion Criteria: * A prior RDN procedure * Diagnosis of secondary hypertension * Any condition for which RDN is contraindicated

Primary outcome measure(s)

  • Change in Office Systolic Blood Pressure (OSBP) — 2 years
    Change in OSBP at two years relative to baseline between matched treated and comparator cohorts.

Trial sites (1)

FacilityCityRegionStatus
Beth Israel Deaconess Medical Center Boston Massachusetts Recruiting

More Medtronic Vascular trials in the USA

Prevail Global Study Recruiting
SPYRAL GEMINI Pilot Study Recruiting
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN Active, not recruiting

Other trials for the same condition

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension Active, not recruiting
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR) Starting soon
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT Recruiting
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07174622 on ClinicalTrials.gov ↗ ← All trials in the USA